Fractyl Health says experimental procedure helps maintain weight-loss in study
Sept 26 (Reuters) - Fractyl Health GUTS.O said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company's shares 23% higher in premarket trading on Friday.
The company was testing the efficacy of its experimental outpatient procedure called Revita, which modifies a part of the small intestine in patients who had stopped tirzepatide, the active ingredient in Eli Lilly's LLY.N weight-loss drug.
The study showed that people who underwent the procedure lost an additional 2.5% weight three months after stopping the drug, while others in the trial who had a sham procedure gained back 10% of their weight, the company said.
The procedure also demonstrated favorable safety and tolerability, Fractyl said.
Revita has U.S. FDA Breakthrough Device designation in weight maintenance for people with obesity who discontinue GLP-1 drugs.
Related Articles
Can $100 Billion Change the Future of AI? The Inside Story of Nvidia and OpenAI’s Mega Partnership
TradingKey - Recently, headlines around the world spotlighted Nvidia’s deal to invest up to $100 billion in OpenAI, a move that’s already being called one of the boldest bets in the history of artificial intelligence.
U.S. Q2 GDP Commentary: Unsustainable Growth Rebound, What’s Next for the Stock Market?
TradingKey - On 25 September 2025, the U.S. released the final Q2 GDP data. The data showed that the annualised quarter-on-quarter real GDP growth rate was 3.8%, surpassing the preliminary estimates of 3% in July and 3.3% in August.
An Overview of U.S. Government Shutdowns: Causes and Consequences
TradingKey - A government shutdown is a uniquely American political event. After former President Donald Trump orchestrated the longest and most costly government shutdown in history during his first term, the risk of another shutdown has resurfaced at the start of his second term.
U.S. August PCE Preview: Four-Run PCE Bounce Challenges the Fed’s Three-Cut Plan
TradingKey - The U.S. Bureau of Economic Analysis (BEA) will release the August Personal Consumption Expenditures (PCE) Price Index on Friday, September 26, with markets closely watching how much tariff pass-through effects have influenced inflation.
U.S. August PCE: Inflation Remains the Market's Greatest Risk
Our baseline forecast anticipates sustained asset price increases. However, if inflation surpasses market expectations in the coming months, it could hinder further rate cuts and pose the greatest risk to financial markets.
